Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554676 | 0.89 | NPSR1 (0.56) | KMT2AMEN1ALDH1A1SLC2A1KDM4E | |
| SCHEMBL11814203 | 0.82 | KMT2A (0.58) | KMT2AMEN1ALDH1A1SLC2A1KDM4E | |
| SCHEMBL11809879 | 0.81 | KMT2A (0.57) | KMT2AMEN1ALDH1A1SLC2A1KDM4E | |
| SCHEMBL5326478 | 0.80 | ADRB2 (0.54) | KMT2AALDH1A1LMNAKDM4EMAPK1 | |
| SCHEMBL10838115 | 0.79 | KMT2A (0.61) | KMT2AMEN1SLC2A1KDM4ENPSR1 | |
| SCHEMBL11811984 | 0.79 | MEN1 (0.61) | KMT2AMEN1ALDH1A1SLC2A1KDM4E | |
| Cloranolol SCHEMBL80494 | 0.77 | SLC2A1 (0.62) | KMT2AMEN1SLC2A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL11815902 | 0.77 | KMT2A (0.60) | KMT2AMEN1ALDH1A1SLC2A1KDM4E | |
| Cloranolol SCHEMBL80493 | 0.77 | SLC2A1 (0.62) | KMT2AMEN1SLC2A1MAPTHTT | |
| Cloranolol SCHEMBL1230788 | 0.76 | KMT2A (0.63) | KMT2AMEN1SLC2A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10788500-B2 | IL1RL-1 as a cardiovascular disease marker and therapeutic target | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20180217160-A1 | IL1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target | THE BRIGHAM & WOMEN'S HOSPITAL, INC. | 2018-08-02 | — | — | US | claimed |
| EP-3072978-B1 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-07-11 | — | — | EP | claimed |
| US-9851362-B2 | 1L1RL-1 as a cardiovascular disease marker and therapeutic target | The Brigham & Women's Hosptial, Inc. (US) | 2017-12-26 | — | — | US | claimed |
| EP-3072978-A1 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET | The Brigham and Women's Hospital, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2336359-B1 | 1L1RL-1 as a cardiovascular disease marker | BRIGHAM & WOMENS HOSPITAL (US) | 2016-04-20 | — | — | EP | claimed |
| US-20150153360-A1 | 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-04 | — | — | US | claimed |
| US-4942161-A | Use of beta blockers for the treatment of the progression of infantile axial myopia | TIBURTIUS HEINFRIED (DE) | 1990-07-17 | — | — | US | claimed |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12440444-B2 | Matrix bound vesicles (MBVS) containing IL-33 and their use | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-10-14 | — | — | US | disclosed |
| US-12383508-B2 | High-purity peg lipids and uses thereof | MODERNATX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4509118-A2 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12151029-B2 | PEG lipids and uses thereof | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2001021259-A2 | USE AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING ANAGRELIDE | EMORY UNIVERSITY (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021163-A2 | METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING MPL PATHWAY INHIBITORY AGENTS | EMORY UNIVERSITY (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001015744-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5086061-A | USE OF BETA BLOCKERS FOR THE TREATMENT OF THE PROGRESSION OF INFANTILE AXIAL MYOPIA | DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH (DE) | 1992-02-04 | — | — | US | disclosed |
| US-4942161-A | Use of beta blockers for the treatment of the progression of infantile axial myopia | TIBURTIUS HEINFRIED (DE) | 1990-07-17 | — | — | US | disclosed |
| EP-0329948-A2 | Use of beta-adrenergic blocking agents in the treatment of the progression of infantile myopia | Dr. Gerhard Mann chem.-pharm. Fabrik GmbH (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | LIPA, LIPG, LIPC | KMT2A 3886/4885MEN1 3410/4885ALDH1A1 1386/4885 |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LNPEP, AUP1, PLTP | KMT2A 3711/4885MEN1 4563/4885ALDH1A1 3649/4885 |
| US-12151029-B2 | PEG lipids and uses thereof | LIPA, LIPG, LNPEP | KMT2A 3721/4885MEN1 3291/4885ALDH1A1 1384/4885 |
| US-12383508-B2 | High-purity peg lipids and uses thereof | LIPA, HDLBP, PLTP | KMT2A 3642/4885MEN1 3560/4885ALDH1A1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.